Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?

[Image: see text] This viewpoint outlines the case for developing new chemical entities (NCEs) as racemates in infectious diseases and where both enantiomers and racemate retain similar on- and off-target activities as well as similar PK profiles. There are not major regulatory impediments for the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera, Diego González, Smith, Dennis A., Basarab, Gregory S., Duffy, James, Spangenberg, Thomas, Chibale, Kelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351050/
https://www.ncbi.nlm.nih.gov/pubmed/37465315
http://dx.doi.org/10.1021/acsmedchemlett.3c00214
_version_ 1785074257446830080
author Cabrera, Diego González
Smith, Dennis A.
Basarab, Gregory S.
Duffy, James
Spangenberg, Thomas
Chibale, Kelly
author_facet Cabrera, Diego González
Smith, Dennis A.
Basarab, Gregory S.
Duffy, James
Spangenberg, Thomas
Chibale, Kelly
author_sort Cabrera, Diego González
collection PubMed
description [Image: see text] This viewpoint outlines the case for developing new chemical entities (NCEs) as racemates in infectious diseases and where both enantiomers and racemate retain similar on- and off-target activities as well as similar PK profiles. There are not major regulatory impediments for the development of a racemic drug, and minimizing the manufacturing costs becomes a particularly important objective when bringing an anti-infective therapeutic to the marketplace in the endemic settings of infectious diseases.
format Online
Article
Text
id pubmed-10351050
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-103510502023-07-18 Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception? Cabrera, Diego González Smith, Dennis A. Basarab, Gregory S. Duffy, James Spangenberg, Thomas Chibale, Kelly ACS Med Chem Lett [Image: see text] This viewpoint outlines the case for developing new chemical entities (NCEs) as racemates in infectious diseases and where both enantiomers and racemate retain similar on- and off-target activities as well as similar PK profiles. There are not major regulatory impediments for the development of a racemic drug, and minimizing the manufacturing costs becomes a particularly important objective when bringing an anti-infective therapeutic to the marketplace in the endemic settings of infectious diseases. American Chemical Society 2023-06-12 /pmc/articles/PMC10351050/ /pubmed/37465315 http://dx.doi.org/10.1021/acsmedchemlett.3c00214 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Cabrera, Diego González
Smith, Dennis A.
Basarab, Gregory S.
Duffy, James
Spangenberg, Thomas
Chibale, Kelly
Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
title Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
title_full Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
title_fullStr Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
title_full_unstemmed Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
title_short Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
title_sort anti-infectives developed as racemic drugs in the 21st century: norm or exception?
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351050/
https://www.ncbi.nlm.nih.gov/pubmed/37465315
http://dx.doi.org/10.1021/acsmedchemlett.3c00214
work_keys_str_mv AT cabreradiegogonzalez antiinfectivesdevelopedasracemicdrugsinthe21stcenturynormorexception
AT smithdennisa antiinfectivesdevelopedasracemicdrugsinthe21stcenturynormorexception
AT basarabgregorys antiinfectivesdevelopedasracemicdrugsinthe21stcenturynormorexception
AT duffyjames antiinfectivesdevelopedasracemicdrugsinthe21stcenturynormorexception
AT spangenbergthomas antiinfectivesdevelopedasracemicdrugsinthe21stcenturynormorexception
AT chibalekelly antiinfectivesdevelopedasracemicdrugsinthe21stcenturynormorexception

Ejemplares similares